Positive Lymph Node Status Before and After Neoadjuvant Chemoradiotherapy Improves Prediction of Disease-Free Survival in Esophageal Squamous Cell Carcinoma Patients.

Background: This study proposes a modified lymph node (LN) staging category (BALN) on the basis of the number of positive LNs before (prepN) and after (ypN) neoadjuvant chemoradiotherapy (nCRT) to improve prognostic stratification in esophageal squamous cell carcinoma (ESCC).

Patients And Methods: A total of 381 patients with ESCC who underwent nCRT at three medical centers were retrospectively enrolled. The ypN categories were scored according to the eighth edition of the American Joint Committee of Cancer (AJCC) staging manual. LNs with regression changes or vital tumor cells were used for interpretation of the prepN stage, reflecting the estimated number of originally involved LNs. BALN category was organized on the basis of the sum of the number of positive LNs in prepN and ypN categories.

Results: BALN category revealed clearer survival classification and prognostic value of disease-free survival (DFS) in patients with ESCC (p < 0.0001). Multivariate cox proportional risk model identified BALN stage as a significant risk factor of DFS of patients with ESCC (p < 0.001). The results of 5-year time-area under the curve (AUC) demonstrated better predictive ability of the BALN category than the ypN category (AUC 0.755 versus 0.707, p = 0.004). The rypTNM system based on BALN category exhibited comparable survival discrimination and better predictive performance than ypTNM system (AUC 0.799 versus 0.756, p = 0.020).

Conclusions: The BALN stage and the revised ypTNM system showed preferable prognosis outcomes to the ypN stage and the ypTNM system, respectively. Evaluating LN status before and after nCRT could allow for more accurate esophageal cancer staging.